Theseus Pharmaceuticals Inc

NASDAQ THRX

Data sourced from

and

Download Data

Theseus Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending September 30, 2023: -44.27%

Theseus Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) 1 year YoY Change (%) is -44.27% for the Trailing 12 Months (TTM) ending September 30, 2023, a 60.03% change year over year. Net Operating Profit After Taxes (NOPAT) is a financial metric that represents a company's operating profit after deducting taxes. It is calculated by multiplying the earnings before interest and taxes (EBIT) by (1 - tax rate). NOPAT provides insights into the company's profitability from its core operations while accounting for the impact of taxes. It is useful for assessing the company's operating performance and comparing profitability across different tax environments. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Theseus Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) for the Trailing 12 Months (TTM) ending September 30, 2022 was -11,350,786.61, a -110.78% change year over year.
Theseus Pharmaceuticals Inc Net Operating Profit After Tax (NOPAT) for the Trailing 12 Months (TTM) ending September 30, 2021 was -5,385,234.30.

NASDAQ: THRX

Theseus Pharmaceuticals Inc

CEO	Dr. Iain D. Dukes D.Phil., DPHIL, M.A.
IPO Date	Oct. 7, 2021
Location	United States
Headquarters	245 Main Street, Cambridge, MA, United States, 02142
Employees	38
Sector	Healthcare
Industry	Biotechnology

Description

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.

Key trends